Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies
Jamie R. Brewer(Center for Democracy in the Americas), Julia A. Beaver(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Diqiong Xie(United States Food and Drug Administration), Harpreet Singh(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Joyce Cheng(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Sundeep Agrawal(Center for Drug Evaluation and Research), Kirsten B. Goldberg(United States Food and Drug Administration), Elaine Chang(Center for Drug Evaluation and Research), Laura L. Fernandes(United States Food and Drug Administration), Chana Weinstock(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Lijun Zhang(Dalian Medical University), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 8
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k